Marina Biotech this week announced that the incorporation of a proprietary technology into an siRNA could reduce toxicity caused by microRNA-like off-target activity.

The approach is based on Marina's unlocked nucleobase analogs, which are comprised of acyclic ribonucleoside analogs in which the bond between C2' and C3' atoms is broken. The resultant change in sugar structure is designed to make the analogs flexible and reduce the binding affinity of siRNA strands.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.